Best Practices in Treatment Selection for Patients With Advanced NSCLC.

Item

http://www.wikidata.org/entity/Q52814108

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Best Practices in Treatment Selection for Patients With Advanced NSCLC.

@en

Best Practices in Treatment Selection for Patients With Advanced NSCLC.

@nl

type

Item

label

Best Practices in Treatment Selection for Patients With Advanced NSCLC.

@en

Best Practices in Treatment Selection for Patients With Advanced NSCLC.

@nl

prefLabel

Best Practices in Treatment Selection for Patients With Advanced NSCLC.

@en

Best Practices in Treatment Selection for Patients With Advanced NSCLC.

@nl

P1476

Best Practices in Treatment Selection for Patients With Advanced NSCLC

@en

P2093

Mark A Socinski

http://www.w3.org/2001/XMLSchema#string

P2860

Tackling ALK in non-small cell lung cancer: the role of novel inhibitors

Non-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?

Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer

Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer

Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes

Evolving Evidence of the Efficacy and Safety of nab-Paclitaxel in the Treatment of Cancers with Squamous Histologies

Bevacizumab in Combination with Taxane versus Non-Taxane Containing Regimens for Advanced/Metastatic Nonsquamous Non-Small-Cell Lung Cancer: A Systematic Review

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular

Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.

P304

2-14

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1073274816023004S01

http://www.w3.org/2001/XMLSchema#string

P433

4 Suppl

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Nathan A Pennell

P577

2016-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27842052

http://www.w3.org/2001/XMLSchema#string

P921

best practice